CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Bure Equity is a situation-based investment company. It was founded in 1992 with the abolition of Sweden’s wage-earner funds. Over its 25-year history, Bure Equity has built a diversified portfolio, comprised of nine companies. The listed companies are the Cavotec engineering group, the MedCap investor in the Life Science sector, the Mycronic electronics designer, the Vitrolife medtech group, and the Xvivo Perfusion medtech company, specialising in transplantation. The Bure Equity unlisted holdings include Bure Financial Services, Bure Growth, Investment AB Bure, and Mercuri International. The Bure Equity group has traded on the NASDAQ Stockholm since 1993. The company’s share price is listed under the BURE ticker in the Mid Cap list. Follow the latest Bure Equity share price trends at Capital.com.
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024
Read our reviews to find out more about us
Read the feedback from our clients, whatever their experience level.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.